Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines  by Panes, J. et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
Journal of Crohn's and Colitis (2013) 7, 556–585CONSENSUS/GUIDELINES
Imaging techniques for assessment of
inflammatory bowel disease: Joint ECCO and
ESGAR evidence-based consensus guidelines
J. Panes a,⁎, Y. Bouhnik b, W. Reinisch c, J. Stoker d, S.A. Taylor e,
D.C. Baumgart f, S. Danese g, S. Halligan h, B. Marincek i, C. Matos j,
L. Peyrin-Biroulet k, J. Rimola l, G. Rogler m, G. van Assche n, S. Ardizzone o,
A. Ba-Ssalamah p, M.A. Bali q, D. Bellini r, L. Biancone s, F. Castiglione t,
R. Ehehalt u, R. Grassi v, T. Kucharzik w, F. Maccioni x, G. Maconi y,
F. Magro z, J. Martín-Comín aa, G. Morana ab, D. Pendsé ac, S. Sebastian ad,
A. Signore ae, D. Tolan af, J.A. Tielbeek d, D.Weishaupt ag, B.Wiarda ah, A. Laghi ra Gastroenterology Department, Hospital Clinic Barcelona, CIBERehd, IDIBAPS, Barcelona, Spain
b Department of Gastroenterology, Beaujon Hospital, Université Paris VII, Clichy, France
c Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna,
General Hospital of Vienna (AKH), Vienna, Austria
d Department of Radiology, Academic Medical Center, Amsterdam, Netherlands
e Department of Imaging 2nd floor, University College Hospital, University College London, London, United Kingdom
f Med. Klinik, Abt. Gastroenterologie/Hepatologie, Charité Campus Virchow-Klinikum, Humboldt-Universität zu Berlin,
Berlin, Germany
g Istituto Clinico Humanitas IRCCS in Gastroenterology, Milan, Italy
h University College Hospital, Level 2 Podium, University College London, London, United Kingdom
i Department of Radiology, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH 44106,
United States
j Department of Radiology, Hopital Erasme, Université Libre, Brussels, Belgium
k Hepato-Gastroenterology University Hospital of Nancy, Nancy, France
l Radiology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
m Klinik für Gastroenterologie und Hepatologie, University Hospital Zurich, Zurich, Switzerland
n Division of Gastroenterology, Mt. Sinani Hospital, Toronto, Canada
o Inflammatory Bowel Disease Unit, Gastroenterology–Oncology–Surgery, L. Sacco University Hospital, Como, Italy
p Department of Radiology, Medical University of Vienna, University Hospital of Vienna (AKH), Vienna, Austria
q Department of Radiology, Hôpital Erasme, Brussels, Belgium
r Department of Radiological Sciences, Oncology and Pathology “Sapienza” University of Rome, Latina, Italy
s Dipartimento di Medicina Interna, Cattedra di Gastroenterologia, Università di Tor Vergata, Rome, Italy
t Gastroenterology, Federico II University, Naples, Italy
u Dep. of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Heidelberg, Heidelberg, Germany⁎ Corresponding author at: Department of Gastroenterology, Hospital Clínic de Barcelona, Villarroel 170, 08036 Barcelona, Spain.
Tel.: +34 932275418.
E-mail address: jpanes@clinic.cat (J. Panes).
1873-9946/$ - see front matter © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.crohns.2013.02.020
557Imaging techniques for assessment of inflammatory bowel diseasev Istituto di Radiologia, Seconda Universitá di Napoli, Naples, Italy
w Innere Medizin und Gastroenterologie, Städtisches Klinikum Lüneburg, Lüneburg, Germany
x Department of Radiological Sciences, Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, Italy
y Gastrointestinal Unit, Department of Clinical Sciences, Luigi Sacco University Hospital, Milano, Italy
z Department of Gastroenterology, Sao Joao Hospital, Porto, Portugal
aa Department of Nuclear Medicine, Hospital Universitari de Bellvitge, Barcelona, Spain
ab Department of Radiology, Ospedale Ca' Foncello, Treviso, Italy
ac UCL Centre for Medical Imaging, University College London Hospital, London, United Kingdom
ad Gastroenterology, Hull & East Yorkshire NHS Trust, Hull, United Kingdom
ae Nuclear Medicine Unit, Faculty of Medicine and Psychology, “Sapienza” University, Rome, Italy
af Clinical Radiology, Leeds General Infirmary, Leeds, United Kingdom
ag Institute of Radiology, Triemli Hospital, Zürich, Switzerland
ah Radiology, Medical Center Alkmaar, Alkmaar, NetherlandsReceived 11 February 2013; accepted 20 February 2013KEYWORDS
Magnetic resonance
imaging;
Computed tomography;
Ultrasonography;
Crohn's disease;
Ulcerative colitis
Abstract
The management of patients with IBD requires evaluation with objective tools, both at the time of
diagnosis and throughout the course of the disease, to determine the location, extension, activity
and severity of inflammatory lesions, as well as, the potential existence of complications. Whereas
endoscopy is a well-established and uniformly performed diagnostic examination, the implemen-
tation of radiologic techniques for assessment of IBD is still heterogeneous; variations in technical
aspects and the degrees of experience and preferences exist across countries in Europe. ECCO and
ESGAR scientific societies jointly elaborated a consensus to establish standards for imaging in IBD
using magnetic resonance imaging, computed tomography, ultrasonography, and including also
other radiologic procedures such as conventional radiology or nuclear medicine examinations for
different clinical situations that include general principles, upper GI tract, colon and rectum,
perineum, liver and biliary tract, emergency situation, and the postoperative setting. The
statements and general recommendations of this consensus are based on the highest level of
evidence available, but significant gaps remain in certain areas such as the comparison of
diagnostic accuracy between different techniques, the value for therapeutic monitoring, and the
prognostic implications of particular findings.
© 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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The idiopathic inflammatory bowel diseases (IBD) comprise two
types of chronic intestinal disorders: Crohn's disease (CD) and
ulcerative colitis (UC). Accumulating evidence suggests that IBD
results from an inappropriate inflammatory response to
intestinal microbes in a genetically susceptible host. The
management of patients with IBD requires evaluation with
objective tools, both at the time of diagnosis and through-
out the course of the disease, to determine the location,
extension, activity and severity of inflammatory lesions, as well
as, the potential existence of complications. This information is
crucial to select appropriate therapeutic strategies in a
particular patient, and has prognostic implications.
Whereas endoscopy is a well-established and uniformly
performed diagnostic examination, the implementation of ra-
diologic techniques for assessment of IBD is still heterogeneous;variations in technical aspects and the degrees of experience
and preferences exist across countries in Europe. This reality
led to the recognition among members of ECCO and ESGAR
scientific societies that practical guidance for the use or
cross-sectional imaging in IBD is needed, and that convergence
of knowledge in the fields of IBD and radiology was necessary
to provide the best evidence-based recommendations. This
joint ECCO–ESGAR project was started on 2010, and developed
during 2011 and 2012 to generate a consensus on imaging in IBD.
The consensus organizing committee was made up by three
members of ESGAR (AL, JS, ST) and three members of ECCO
(YB, JP, WR) providing a broad national diversity.
The aimof the projectwas to establish standards for imaging
in IBD using magnetic resonance imaging (MRI), computed
tomography (CT), ultrasonography (US), and including also
other radiologic procedures such as conventional radiology or
nuclear medicine examinations, but not endoscopy, although
559Imaging techniques for assessment of inflammatory bowel diseaseconsiderations on the relative value of endoscopy and radiology
in different clinical settings are provided in the consensus.
The strategy to develop the consensus involved 5 steps:1. The consensus organizing committee identified 7 main
topics on the use of imaging in IBD that included:
1. Overview.General principles. Technical aspects. Scores.
Radiation safety.
2. Upper GI tract (including esophagus, stomach, duode-
num) & small bowel.
3. Colon and rectum, CD and UC including severe colitis.
4. Perineum including anus, genital tract.
5. Liver and biliary tract.
6. Emergency situation (acutely ill patients to be treated/
investigated within 24 h).
7. Special situations: postoperative setting, cancer surveil-
lance, and ileoanal pouch.
Uniform questionswere addressed for each topic, taking into
consideration the procedures available; patient acceptance,
tolerability, complications; costs in Europe; definitions of ele-
mentary abnormalities, value for diagnosis, value for detection
of inflammation (activity) and bowel damages; value for detec-
tion of complications, value for therapeutic monitoring and
prognostication; information needed for the gastroenterologist,
and positioning of imaging techniques in a diagnostic algorithm.
A working group was created for each topic composed of gastro-
enterologists (ECCO members) and radiologists (ESGAR mem-
bers). Participants were asked to answer the questions based
on evidence from the literature as well as their experience.
ECCO participants were selected by the Guidelines' Commit-
tee of ECCO (GuiCom) among responders to an open call (see
acknowledgements and www.ecco-ibd) on the basis of their
publication record and a personal statement. ESGAR partici-
pants were selected by the governing Board of the society.
2. The working groups performed a systematic literature
search of their topic with the appropriate key words
using Medline/Pubmed and the Cochrane database, as
well as their own files. The evidence level (EL) was
graded according to the 2011 review of the Oxford
Centre for Evidence Based Medicine.1
3. Revised statements on their topic were then written by the
Chairs, based on answers from their working party, as well
as the literature evidence and were circulated first among
their working group and then among all participants.
4. All working groupsmet in Vienna on January 2012 to approve
the final version of each statement. Technically this was
done by projecting the statements and revising them on
screen until a consensus was reached. Consensus was
defined as agreement by N80% of participants, termed a
Consensus Statement and numbered for convenience in the
document. Two members of the European Association of
Nuclear Medicine (JM-C, AS) were integrated as participants
in the consensus project at this stage.
5. The final document on each topic was written by the Chairs
in conjunction with their working party. Consensus state-
ments in bold are followed by comments on the evidence
and opinion. Statements are intended to be read in context
with qualifying comments and not read in isolation. The
final text was edited for consistency of style by Andrea
Laghi and Julián Panés before being circulated and
approved by the participants.2. General principles. Technical aspects.
Radiation safety
2.1. General principlesECCO–ESGAR statement 2A
Radiological imaging techniques are complementary
to endoscopic assessment. Cross-sectional imaging
offers the opportunity to detect and stage in-
flammatory, obstructive and fistulizing CD and is
fundamental at first diagnosis to stage disease
and to monitor follow-up [EL 1].
The diagnosis IBD is based on a combination of endoscopic,
histological, radiological, and/or biochemical investigations
as a single gold standard is missing.2 For suspected IBD,
ileocolonoscopy and biopsies from the terminal ileum as well as
from each colonic segment are the first line procedures to
establish the diagnosis.2 CD may affect segments of the small
bowel beyond the reach of ileocolonoscopy, may hamper the
advance of the scope due to strictures ormay be complicated by
extra-mural lesions of the intestine or in the perineal region
(including fistulas and abscesses) not amenable to endoscopic
visualization. Thus, cross-sectional imaging techniques are an
important adjunct to endoscopic assessment, to allow a
complete and sensitive staging of the small bowel and perineum
with the unique advantage to assess mural and extramural
disease.3
The applications of cross-sectional imaging techniques in
IBD are manifold. In cases of suspected CD cross-sectional
imaging of the small bowel is recommended to detect, stage
and classify disease behavior.2,3 In established CD it assists to
select treatment, to assess response and to quantify tissue
damage.3,4 In perianal fistulizing CD it complements the
examination under anesthesia by an experienced surgeon. In
suspected UC with a discontinuous endoscopic appearance of
colonic inflammation cross-sectional imaging should be con-
sidered to exclude small bowel inflammation indicating the
differential diagnosis with CD.22.2. Technical aspects
2.2.1. UltrasonographyECCO–ESGAR statement 2B
US is a well-tolerated and radiation-free imaging
technique, particularly for the terminal ileum and
the colon. Examinations are impaired by gas-filled
bowel and by large body habitus [EL 2].
US is also a technique to guide interventional
procedures (e.g., abscess drainage) [EL 2].
US is non-invasive, does not impart ionizing radiation,
and is well tolerated and accepted by patients. Bowel
560 J. Panes et al.examination may be hampered by air, the volume of which
may be reduced by recommending the patient to fast at
least 6 h before the examination. The use of laxative and
non-flatulent preparations is not required before routine
abdominal ultrasound.5
Specific preparations with the oral administration of
intraluminal contrast can improve image quality and diagnos-
tic accuracy.6 Oral intake is generally better accepted by
patients than techniques using small bowel intubation, and
non-absorbable fluid should be used to reduce the volume
needed.6
US for IBD requires high-frequency (5–17 MHz) linear array
probes to increase spatial resolution and to allow adequate
assessment of bowel diameter and of the recognizable 5-layer
wall pattern.7 A systematic approach to search for intestinal
wall abnormalities is recommended including four scanning
positions in the upper and lower, right and left abdominal
quadrants. The ileocecal region, sigmoid and often ascending
and descending colon are adequately visualized in most
patients. The proximal ileum and jejunum can be difficult
to assess due to multiple overlying bowel loops and deep
pelvic location, whereas the study of transverse colon
is challenging because of its variable anatomy, and the
rectum for accessibility.
Contrast-enhanced US (CEUS) may improve diagnostic
accuracy and diagnostic confidence in detecting inflamma-
tory activity.8,9
Ultrasound is a validated technique to guide interventional
procedures. For example percutaneous or transrectal abscess
drainage under sonographic guidance has a high technical
success rate of 96%.10–12 Moreover, ultrasound can be useful
to detect and drain pyogenic liver abscess.11,13 and is also
suitable to guide insertion of intravenous lines, particularly in
pediatric patients.14
Demonstration and communication of the extent of
abnormality and comparison between studies at clinical/
radiology/nuclear medicine conference are generally
easier with other imaging modalities, such as CT and
MRI.
2.2.2. Computed tomographyECCO–ESGAR statement 2C
CT of the abdomen and pelvis in order to assess
the small intestine and colon requires luminal
distension, and intravenous contrast administra-
tion. Radiation exposure is the major limitation.
CT can be used to guide interventional procedures
(e.g. abscess drainage) [EL 2].CT of the small intestine and colon is performed using a
multidetector-row scanner able to cover the required
anatomical region within a single breath-hold. Rapid
image acquisition minimizes motion and peristaltic arti-
facts. Imaging protocol includes thin detector collimation
and slice thickness (in order to benefit from multiplanar
reformats).15–17
The use of intravenous injection of contrast medium is
important for the assessment of bowel wall enhancementpattern and mesenteric vessels.16,18,19 Bowel distension is
a fundamental requisite for any imaging method of the
small intestine, since collapsed bowel loops can either hide
lesions or simulate pathological wall thickenings.20–22 Luminal
distension can be achieved with enteric contrast agents, either
positive or neutral. Neutral contrast agents, which possess
X-ray attenuation similar to water, are preferred for most of
the clinical indications.23–25 To minimize absorption, water is
usuallymixedwith highmolecular size compoundswhich do not
alter water density and taste, such as polyethylene glycol
(PEG), mannitol, sugar alcohols or sorbitol. Positive contrast
agents are usually a mixture of barium sulfate (1–2%) or
iodinated contrast agents (2–3%). In IBDs positive enteral
agents are preferred for the evaluation of perforations or
fistulas.26,27
Enteric contrast agents can be administered orally (CT
enterography) or injected through a naso-jejunal tube (CT
enteroclysis). CT enterography is faster, less demanding for
radiologists and has superior patient acceptance compared
with enteroclysis. CT enterography provides good distension
of mid-terminal ileum, but offers limited distention of the
jejunum.25 Diagnostic performances are similar in CD,
although CT enteroclysis has higher specificity, but also a
slightly higher radiation burden because of the additional
exposure associated with naso-jejunal tube placement under
fluoroscopy guidance.25
Radiation exposure is the major limitation of CT, particu-
larly in patients undergoing repeated examinations.28,29 The
use of new dose reduction techniques, like adaptive statistical
iterative reconstruction, should be recommended especially
in younger patients.28,29
CT is also useful to guide interventional procedures such as
percutaneous drainage of intraabdominal abscess or pyogenic
liver abscess.11 Although use of surgery remains common in
such patients, radiologically (CT) guided nonsurgical therapy
is of increasing importance.30–342.2.3. Magnetic resonance imagingECCO–ESGAR statement 2D
MRI of the small bowel and colon requires fast
imaging techniques and luminal distension [EL 2].
MR enterography/enteroclysis has similar diagnos-
tic accuracy and similar indications to CT, but with
the major advantage of not imparting ionizing
radiation [EL 1].
MRI of the small bowel and colon requires fast sequences, able
to acquire T1- and T2-weighted images within a single breath
hold, and limiting motion and peristaltic artifacts.20-21 The
use of intravenous injection of contrast medium is manda-
tory for the assessment of bowel wall enhancement pattern
and mesenteric vessels.
Diffusion-weighted imaging is feasible in UC and CD, even
without bowel preparation, and has utility for detecting
colonic inflammation.35,36 The inclusion of small bowel
motility evaluation may increase lesion detection rate
compared with static MRE alone.37,38
561Imaging techniques for assessment of inflammatory bowel diseaseSimilarly to CT, enteric contrast agents can be adminis-
tered orally (MR enterography) or injected through a
naso-jejunal tube (MR enteroclysis).39 Enteric contrast agents
can be classified according to the action on the signal intensity
of bowel lumen into positive, negative and biphasic agents.
The use of positive agents has been largely abandoned, and
currently both biphasic and negative contrast agents are
widely used.40 Biphasic contrast agents include several
non-absorbable iso-osmolar solutions [poly-ethylene glycol or
mannitol solutions], which produce a negative effect on
T1-weighted and a positive effect on T2-weighted images
(“water-like” effect), providing satisfactory dilation of the
small bowel without side effects, excluding mild laxation.
Negative contrast agents, made of a superparamagnetic non-
absorbable solution of iron oxide particles, markedly reduce
the signal of the intestinal lumen, both on T1 and T2 weighted
images (“black lumen” effect).41–44
Pelvic MRI using high resolution T2-weighted images and
contrast-enhanced T1-weighted images is the imaging
modality of choice for the evaluation of perianal disease,
fistula, and adjacent abscesses; it is superior to anal
endosonography, CT or surgical evaluation for showing
disease extent.45,46
CT and MRI have a similar diagnostic accuracy for imaging
IBD.47,48 CT has greater availability and is less time consuming
than MRI.2.2.4. Nuclear medicine techniquesECCO–ESGAR statement 2E
NM procedures especially WBC scintigraphy are an
alternative to cross-sectional imaging for evalua-
tion of disease activity and extension in specific
situations [EL 2].
Radiation exposure is the major limitation of NM
procedures [EL 2].
PET/CT with FDG is poorly specific for inflamma-
tion and for assessing disease activity [EL 3].
Scintigraphy with radiolabeled leukocytes (WBC) is useful in
the diagnosis of IBD, and in particular to evaluate disease
extension and activity.49–58 A normal scanmakes the presence
of active IBD very unlikely.49–58 WBC scintigraphy explores the
whole intestine in a single image and with relatively low
radiation exposure (2–4 mSv/exam)59 so may be particularly
suited to the investigation of children.53,60
WBC scintigraphy has demonstrable utility in the
follow-up and for evaluating response to treatment,
particularly in patients with UC.50,52 After surgery, it can
be used to differentiate between disease relapse and
fibrotic tissue.61,62
In some countries WBC scintigraphy is substituted with
the anti-granulocyte monoclonal antibody scintigraphy.
However, the latter showed lower sensitivity and specific-
ity than labeled leucocyte scintigraphy for evaluation of
IBD.49
The role of PET/CT with FDG has not yet been clearly
established.63–652.2.5. Barium contrast radiologyECCO–ESGAR statement 2F
Small bowel follow-through and enteroclysis have
high accuracy for mucosal abnormality and are
widely available. They are less able to detect
extramural complications and are contraindicated
in high grade obstruction and perforation. Radia-
tion exposure is a major limitation [EL 2].
Barium contrast examinations are long established for small
bowel evaluation and are in widespread use66 using either
SBFT or SBE techniques. SBFT may be augmented by
pneumocolon to produce double contrast imaging.67 SBE is
inherently more invasive with tube placement resulting in a
higher radiation exposure compared with SBFT.68 Although
the radiation exposure for barium studies is lower than for
CT, it is nevertheless a significant exposure for adults69 and
children70 particularly where repeated examinations are
performed. Moreover, excessive fluoroscopy time and number
of abdominal radiographs can result in actual doses that are
equivalent to CT.70 Both techniques have acceptable accuracy
in the depiction of strictures and ulceration related to CD
comparedwith other techniques71–73 and to date have acted as
a benchmark for comparison with other modalities.47 Direct
comparison indicates superiority of SBFT over SBE for detection
of mucosal detail and fistula.74 Extramural complications
including internal fistulas may be identified75 but other
extramural complications such as abscess are not reliably
demonstrated compared with other modalities.76 Wide
availability and low cost are advantages but barium is
contraindicated in high-grade obstruction and bowel per-
foration, which limits the role of this modality in patients
with acute presentation. While other imaging modalities
have advantages, SBFT remains an acceptable method of
small bowel assessment where access to other techniques is
limited.2.2.6. Plain film radiologyECCO–ESGAR statement 2G
Plain films have a role in the assessment of
specific emergency cases [EL 3].
Plain abdominal radiographs have been routinely used in the
assessment of patients with IBD for many years. However the
status of plain film radiography in the triage of patients with
the acute abdomen is diminishing in favor of US and CT77
particularly with the development of low dose CT tech-
niques.78,79 Data on the accuracy of plain films is limited to
small series. Furthermore conclusions are conflicting both in
terms of accuracy for assessment of the distribution and
severity of colitis (by assessment of the extent of fecal residue,
dilatation and wall thickening)80–82 and for locating and
defining the etiology of small bowel obstruction (by detection
of small bowel dilatation).83–85 Plain abdominal and chest
radiographs may detect perforation but cannot determine the
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intra-abdominal free gas.86–88
Plain films have no role in the routine assessment of
non-emergency clinical presentations due to their failure to
adequately assess the distribution or activity of disease.
Where out of hours access to other imaging modalities
services is limited, plain films can help direct clinical
decision-making in the acute setting. However where
findings are equivocal, other more accurate imaging modal-
ities should be used, in particular where radiographs fail to
demonstrate abnormalities in a patient with high clinical
suspicion of an acute abdominal complication related to
known IBD.2.3. Radiation exposureECCO–ESGAR statement 2H
High radiation exposure and earlier age of exposure
both increase the risk of radiation-induced cancer
[EL 2].
Independent predictors of increased radiation ex-
posure in IBD patients are: diagnosis of CD, need of
steroids, IBD related surgery, increasing severity,
upper gastrointestinal tract involvement, the first
year following diagnosis and young age of disease
onset [EL 2].
Repeated CT examinations, particularly in children and
young patients, may expose those individuals to an increased
life-time radiation-induced cancer risk.89,90 The chronically
progressive nature of IBD which results in intestinal damage,
hospitalizations, surgery and the screening for infections or
disease complications determines higher levels of annual
and total diagnostic radiation exposure particularly due to
use of CT in patients with CD and UC.91 Patients with CD
have a higher cumulative radiation exposure than patients
with UC.92 According to a recent meta-analysis the pooled
prevalence of IBD patients receiving potentially harmful
levels of radiation (defined as ≥50 mili-Sieverts, mSv), was
8.8% (11.1% and 2% for CD and UC, respectively). IBD-related
surgery and corticosteroid use were significant risk factors
with pooled adjusted odds ratios of 5.4 (95% CI 2.6–11.2) and
2.4 (95% CI 1.7–3.4) respectively.93 Other factors noted to
be associated with a high cumulative effective dose were
age b17 years at diagnosis, the first year after diagnosis,
upper gastrointestinal tract disease, penetrating disease,
use of infliximab and multiple surgeries.17,94
In clinical practice the appropriateness of CT use should
be scrutinized, particularly in young patients and when
alternative modalities with acceptable accuracy are
available.90
Low-dose CT examinations (b2 mSv) are now possible due
to the development of new techniques based on adaptive
statistical iterative reconstruction method. Iterative methods
allow significant radiation dose reduction without sacrificing
image quality as compared with filtered back projection
alone.15,29,952.4. Availability of techniquesECCO–ESGAR statement 2I
CT, US and SBFT are generally more available and
less expensive than MRI and scintigraphy [EL 4].
Unfortunately availability is still currently limited to a few
diagnostic centers,3,29 although as dissemination occurs, the
role of CT in IBD may be reviewed.
Availability of equipments and expertise of interpreting
personnel are generally greater for CT, US and SBFT in
comparison with MRI and WBC scintigraphy. The major
limitation of WBC scintigraphy is the limited availability.
3. Upper GI tract & small bowel
3.1. Techniques for examination of upper GI and
small bowelECCO–ESGAR statement 3A
SBE, SBFT, US, CT, MRI and WBC scintigraphy are
able to detect signs of Crohn's disease [EL 1].
US, CT, and MRI have a high and comparable
diagnostic accuracy at the initial presentation of
terminal ileal CD [EL 1].
SBE and SBFT have an acceptable accuracy for
mucosal disease but are less accurate for mural
disease and extramural complications [EL 3].
ECCO–ESGAR statement 3B
US, CT, MRI and WBC scintigraphy can be used to
assess disease activity in Crohn's disease of the
terminal ileum [EL 1].
MRI, CT and WBC scintigraphy are able to explore
the entire length of the small bowel whereas US
has a more limited coverage [EL 4].3.1.1. Small bowel enteroclysis (SBE) and small bowel
follow-through (SBFT)
Historically, SBE and SBFT examinations have been the
standard radiologic approaches used to assess patients with
suspected or established CD. Radiologic findings include
irregular thickening and alteration of the circular folds,
narrowing of the bowel lumen with presence of ulcerations,
loop adhesions or separation because of wall thickening and
mesenteric inflammatory infiltration.96
SBE has been shown to be highly accurate, with 95%
sensitivity and 96.5% specificity in diagnosing small bowel
disease using MR enteroclysis as reference standard.97 In
severe cases of CD with clinical suspicion of septic complica-
tions such as abdominal mass or fever, the accuracy of SBE for
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80.3% against a reference standard of intraoperative
findings.75
Some investigators have compared SBFT with SBE studies
and reported comparable results.98 In a prospective study, it
was concluded that SBFT is safer, preferred by patients, and
is less likely to miss gastroduodenal disease compared to
SBE. A normal SBFT obviated the need to perform SBE.74
However, other researches have suggested that SBE is more
accurate than SBFT at detecting early mucosal lesions.99–100
Both methods provide only limited and indirect information
in regard to the state of the bowel wall and extraluminal
extension of CD. Although barium imaging manages to accu-
rately detect the location and extension of CD, it is not as
accurate as other radiologic imaging modalities in providing
information on extraluminal manifestations.76,101
3.1.2. Ultrasound
US diagnosis of CD relies on several features, but primarily
on the detection of increased bowel wall thickness, which is
considered the most common and constant US finding in
CD.102 The importance of this sign for the accuracy of US
diagnosis of CD has been evaluated in several studies and
sensitivities of 75–94% with specificities of 67–100% have
been reported.103–105 In a meta-analysis of seven prospec-
tive and appropriately designed studies (five case control
and two cohort studies), it was shown that when N3 mm
cut-off level was applied for abnormality in wall thickness,
the sensitivity and specificity of US in the diagnosis of CD
were 88 and 93%, while when a cut-off level of N4 mm was
used, sensitivity was 75% and specificity 97%.106 In a recent
systematic review,36 the overall per-patient sensitivity of US
for the diagnosis of CD was 85% (95% CI 83–87%). Overall per
patient specificity derived from studies reporting this metric
was 98% (95% CI 95–99%).
The use of intraluminal orally administered contrast
agents, such as iso-osmolar polyethylene glycol solution at
a dose ranging from 500 to 800 ml, has also been proposed to
better define CD. While the use of intraluminal contrast
appears to reduce intraobserver variability and increase
sensitivity in defining disease extension, location and intesti-
nal complications in patients with established CD, its value in
the early diagnosis of CD has not been proven.107,108
3.1.3. Computed tomography
The accuracy of CT (either CT enteroclysis or CT
enterography) for diagnosing CD in patients with a suspected
diagnosis has been investigated in several prospective studies.
A good correlation has been shown between CT and histopa-
thology results in regard to inflammatory changes (Spearman's
r = 0.7, P b 0.0001), but no details were provided for signs of
fibrostenosis.109 CT variables associated with inflammation
were mucosal enhancement, wall thickness, comb sign, and
presence of enlarged lymph nodes (P values 0.04, 0.04,
b0.0001, and 0.016, respectively). Solem et al. reported
the results of a prospective, blinded randomized controlled
trial that compared the utility of four primary small-bowel
imaging modalities: CT, ileocolonoscopy, capsule endoscopy
(SBCE) and SBFT as diagnostic tools for CD. The researchers
aimed to administer all four tests to 41 patients with known or
suspected small-bowel CD over a 4-day period.73 Of the 41
patients enrolled, only 26 underwent all four tests. Sensitivitywas not significantly different between the techniques
(83% for SBCE, 67% for CT and ileocolonoscopy, and 50% for
SBFT). Specificity was significantly lower in SBCE (53%)
than in all other tests (100%, P b 0.05 for all). The authors
concluded that a combination of at least two diagnostic
techniques (preferably ileocolonoscopy plus CT) should be
implemented as first-line diagnostic assessment of small-
bowel CD. In addition small bowel radiological imaging,
preferably using CT or MRI, is needed prior to SBCE
because of the high frequency of asymptomatic stenosis in
suspected or known CD patients, risking capsule retention,
and because these techniques can also detect extraluminal
complications.73,110,111
3.1.4. Magnetic resonance imaging
MRI allows for an accurate assessment of the small bowel
without radiation exposure, making this imaging tool ideally
suited to the CD population given their age and need for
repeated imaging.
MRI changes associated with the presence of inflam-
mation include wall thickening, wall hyper-enhancement
after injection of MRI contrast medium, presence of wall
edema, and presence of ulcers, as well as extramural
changes such as presence of comb sign, fat stranding and
enlarged lymph nodes.112 A systematic review reported
per-patient sensitivity and specificity of MRI for the
diagnosis of CD as 78% (95% CI 67–84%) and 85% (95% CI
76–90%) respectively.36
3.1.5. Nuclear medicine
The use of radiolabeled WBC scintigraphy provides informa-
tion about the presence of an inflammatory process in the
small and large bowel as well as its extent.58 Leucocytes are
labeled in vitro using 99mTc-HMPAO or 111In-oxine, and the
technique entails a low radiation exposure. 99mTc-HMPAO
is the first option due to the highest availability and lower
radiation burden.113 The accumulation of labeled leuko-
cytes identifies the presence of active disease within
the bowel or other complications such as fistulae or
abscess.56,57,114
FDG-PET/CT might be used for early therapy follow-up
particularly in non-complicated IBD eligible for biological
treatment. Nevertheless, while preliminary literature data
suggest that PET/CT with FDG has a clinical value in adults
and pediatric patients, there is at present not enough
evidence to support its use in clinical practice.49,63,64,115
3.1.6. Comparison of SBE, SBFT, US, CT, MRI and
scintigraphy
In a recent study, SBFT, CT and MRI were compared and
appeared to be equally accurate in the identification of
active inflammation in the small intestine. Although the
sensitivity values of CT (89%) and MRI (83%) were slightly
higher than those of SBFT (67%–72%) with regard to active
terminal ileitis, these differences were not significant.76
A meta-analysis comparing the accuracies of US, MRI,
scintigraphy, CT, and PET for diagnosis in patients with
suspected or known IBD, mainly CD,47 showed that mean
sensitivity estimates for the diagnosis of IBD on a
per-patient basis were high and not significantly different
among the imaging modalities (90%, 93%, 88%, and 84% for
US, MRI, WBC scintigraphy, and CT, respectively). Mean
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MRI, 85% for leucocyte scintigraphy, and 95% for CT; the
only significant difference in values was that between
scintigraphy and US (P = 0.009). Mean per-bowel-segment
sensitivity estimates were lower: 74% for US, 70% for MRI,
77% for WBC scintigraphy, and 67% for CT. Mean
per-bowel-segment specificity estimates were 93% for US,
94% for MRI, 90% for WBC scintigraphy, and 90% for CT. CT
proved to be significantly less sensitive and specific compared
with WBC scintigraphy (P = 0.006) and MRI (P = 0.037). There
were no studies selected in which the accuracy of PET
for the diagnosis of IBD was assessed. The authors
concluded that no significant differences in diagnostic
accuracy among US, CT, MRI and WBC scintigraphy were
observed.3.2. Assessment of stenotic lesionsECCO–ESGAR statement 3C
US, CT and MRI and SBE / SBFT have a high
sensitivity and specificity for the diagnosis of
stenosis affecting the small bowel [EL 2].
Diagnostic accuracy of MRI and CT for stenosis is
based on the use of luminal contrast. In partially
obstructing stenosis, enteroclysis may provide
higher sensitivity than enterography [EL 2].
Cross-sectional imaging using CT, US, MRI [EL 2] and
WBC scintigraphy [EL 3] may assist in differentiating
between predominantly inflammatory or fibrotic
strictures [EL 5].
The definition of a stenosis may be relatively simple for an
endoscopist who can record the inability or difficulty to
advance the endoscope through a narrowing of the bowel
lumen. Unfortunately, such an assessment is not the same
for imaging and the definition of stenosis has varied in
different studies. Stenosis is usually defined as a thickening
of the bowel wall with a narrowing of the small bowel
lumen, and some definitions include also the presence of
the dilation above of the narrowing.2,116 Others rank bowel
stenosis as high grade (80%–100% narrowing of normal
lumen), intermediate (60%–80%), low grade (50%–60%) and
absent (0–50%).117
SBFT and SBE show a low albeit significant correlation with
surgical findings in identifying the number, localization, and
extension of stenosis. These examinations may identify small
bowel obstruction, but cannot depict the cause, indicating
additional diagnostic work up often based on MRI or CT.2 In
addition they have a considerably lower sensitivity for the
detection of small bowel and extraluminal complications
compared to CT or MRI.73,109,116,118
In experienced hands, bowel US is an accurate technique
for detection of small bowel stenosis, especially high grade
stenosis that may be candidates for surgery.116 Based on the
pooled data of three studies using surgery as reference
standard, the sensitivity of US was 79% and specificity was
92%.36Use of oral contrast agents can improve the accuracy of
US in detecting the presence and number of small-bowel
stenoses (sensitivity increased from 74% to 89% in one
study),116 but it is generally not necessary in patients with
symptomatic obstruction.
In two studies comparing CT with ileocolonoscopy and
capsule endoscopy, the sensitivity of CT for the detection of
stenoses was 92% and specificity 100%.73,111 Two additional
studies using endoscopy and surgery as a reference stan-
dard119,120 reported a sensitivity of 85% and 90%, respectively
and both a specificity of 100%.
Direct comparison of CT and MRI for diagnosis of stenosis
in a study with 44 patients showed also a similar sensitivity
(85% vs. 92%) and specificity (100% vs. 90%).119 Pooled
results of seven studies with adequate reference standard
(endoscopy and/or surgery), showed that the sensitivity of
MRI for diagnosis of stenosis was 89% and specificity 94%.36
Better distension was achieved with MR enteroclysis than
with MR enterography resulting in a higher sensitivity (100
versus 86%, respectively) and specificity (100% versus 93%)
for detecting stenosis, though the difference was not
significant.39
When performing CT or MRI before capsule endoscopy,
between 27 and 40% of patients are excluded from capsule
endoscopy due to the identification of a stenosis.111,121
Over and above diagnosing the presence of a stenosis,
determining the relative inflammatory and fibrous compo-
nent of a stenosis may be helpful for guiding therapy.
The perfusion of the intestinal wall involved in CD can
effectively be studied with CEUS Dynamic evaluation of
the bowel wall enhancement using CEUS can be
performed with high temporal resolution and has been
reported to correlate with the inflammatory activity in
the intestinal wall in some studies,122 although not in
others.123
In a study evaluating CT classification of lesion type
using histopathology of surgical specimens as reference
standard,109 it was shown that wall thickness, parietal
enhancement, comb's sign and the presence of enlarged
lymph nodes were correlated with the presence of
inflammatory lesions, and it was only the presence of a
stenosis that was associated with fibrotic changes in the
intestinal wall. The study did not provide any means to
differentiate between inflammatory and fibrous compo-
nents of a stenotic lesion. Another study that compared CT
findings with histology stated that small bowel stenoses,
without CT findings of inflammation do not predict the
presence of fibrosis. Therefore, CT criteria cannot be used
to predict the presence of fibrous component in a stenotic
lesion.124
A recent study evaluated the value of MRI findings in
small bowel CD in correlation with 52 surgical pathology
specimens.118 The MRI signs significantly associated with the
presence of fibrosis were wall thickness, T2 hyperintensity,
comb sign and fistula. However, these findings were not
reproduced in another study, in which no correlation was
found between wall thickness and T2 hyper intensity with
fibrosis, although in that study a layered enhancement
pattern was common in fibrostenotic segments.125 Overall,
in contrast with well-established MRI criteria for determin-
ing presence and severity of inflammation no validated
criteria have been established to reliably determine the
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MRI.
3.3. Assessment of penetrating lesionsECCO–ESGAR statement 3D
US, CT, and MRI have a high accuracy for the
assessment of penetrating complications (i.e.,
fistula, abscess) [EL 1] and for monitoring disease
progression [EL 4].
For deep-seated fistulas MRI and CT are prefera-
ble to US [EL 4].
US and CT are widely available and facilitate early
abscess drainage [EL 4].
WBC scintigraphy may provide useful information
when cross sectional imaging is inconclusive for
detecting abscesses [EL 3].
ECCO–ESGAR statement 3E
MRI demonstrates high agreement with conven-
tional radiology (i.e. SBE and SBFT) and CT for the
diagnosis of superficial and transmural abnormal-
ities. MRI is superior to conventional radiology for
assessing the extramural manifestations, and has
the advantage over CT of avoiding radiation
exposure [EL 2].3.3.1. Fistula
At the time of diagnosis 15.5% of patients with CD have
penetrating lesions (fistulas, phlegmons or abscesses).126 In
a systematic review, pooled results of four US studies for the
diagnosis of fistulizing lesions, using surgery (in three studies)
and barium studies, surgery, or/and colonoscopy (in one
study) as reference standard, showed a sensitivity of 74% and
specificity of 95%.36 The largest study, using surgery as
reference standard, included 128 patients with 119 internal
fistulas. US showed a sensitivity of 71% and specificity of
96%.75 In this study, US and SBE had the same accuracy for the
detection of internal fistulas (85%). Using the combination
of US and SBE, and also considering the presence of fistulae
when revealed by at least one method, the sensitivity in
diagnosing this complication rose to 90%. The addition of
oral contrast agents, does not improve the accuracy of US
for the detection of internal fistulas.108 US may be used for
detection of extramural complications of CD, although if CT
or MRI is available, they are preferable for the detection of
intra-abdominal fistulas.2
The sensitivity of CT for the diagnosis of fistulas has been
reported in a systematic review. This showed that, based on
the pooled results of five studies with surgery and endoscopy
as reference standard, the sensitivity was 70% and specific-
ity 97%.36 Two studies although not meeting the selection
criteria of this systematic review, used surgical findings as
the reference standard and reported higher accuracies fordiagnosis of fistulas. In one of these studies including 44
patients, the sensitivity, specificity, and accuracy of CT for
the detection of small bowel fistula were 77.8%, 86.8%, and
85.1%, respectively.109 The other study included 36 patients,
the presence or absence of a fistula was correctly determined
by CT in 94%.127
The key role of cross-sectional imaging for assessment of
penetrating complications of CD is demonstrated in a
retrospective study including 56 patients, showing that in
half of the patients with penetrating complications of CD,
there was no suspicion of a fistula or abscess at pre-CT
clinical assessments, with 79% of these patients subsequently
receiving new medical therapy or undergoing surgical or
percutaneous intervention based on the detection of pene-
trating CD on CT.128
MRI is highly accurate for the detection of abscesses,
fistulae and inflammatory infiltrates in CD.129,130 Pooled
results of four studies with adequate reference standard
(endoscopy and/or surgery) showed a sensitivity of MRI for
the diagnosis of fistulas of 76% and specificity of 96%.36
Other studies on MRI for diagnosing intra-abdominal fistulas
have been published,76,118,131–133 but only one used surgical
findings as the reference standard.118 Detection of small-bowel
fistula by MRI had a sensitivity, specificity, and accuracy of
88%, 93%, and 91%, respectively, but the authors did not
differentiate between abscess and fistula.118 MRI actually
appears to be themost efficient tool to detect intra-abdominal
fistulas, and CT and MRI are the recommended techniques for
detection of extramural complications of CD.2
A WBC scintigraphy has no indication for the diagnosis and
characterization of fistulae.
3.3.2. Abscess
Pooled results in a systematic review of three US studies
for the diagnosis of abscesses using surgery as a reference
standard reported a sensitivity of 84% and a specificity of
93%, although US accuracy has been reported to be highly
related to disease location in CD.36 In clinical practice, if
an intra-abdominal abscess or deep-seated fistula is
suspected, US should be used only if CT or MRI is not
available or in children in whom other methods are less
feasible.
CT and US showed an overall high and comparable
accuracy in the detection of intra-abdominal abscesses,
although CT showed a slightly greater positive predictive
value than US. CT has been reported to determine the exact
location and extent of an abscess with great reliability. Only
two studies had surgery as reference standard for detection
of extra-enteric lesions on CT,75,109. One study showed that
for the detection of intra-abdominal abscesses the sensi-
tivity, specificity, and accuracy of CT compared with
surgical findings were 85.7%, 87.5%, and 87.2%, respec-
tively.75 In another prospective study, intra-abdominal
abscesses were found intra-operatively in 22 patients and
sensitivity of CT for the diagnosis of abscesses was 85% and
specificity 95%.109 Because of its accuracy, ability to detect
penetrating complications of CD, and high availability, CT is in
clinical practice the most useful imaging modality to detect
intra-abdominal abscesses in CD.
Only three studies used surgery as the reference standard to
assess the accuracy of MRI in detection of an abscess.76,118,132
Sensitivity ranged from 86% to 100% and specificity from 93% to
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than five patients with intra-abdominal abscess76,131 and the
third did not differentiate abscess from fistula.134 Pooling the
results of these three studies showed a sensitivity of MRI for the
detection of abscesses of 86% and a specificity of 93%.36
The access to MRI remains limited in some countries and
image acquisition and analysis still takes longer than for CT
(although recent developments have decreased the image
acquisition time to 15–30 min). These reasons may limit the
use of MRI as a first line examination to detect intra-abdominal
abscess in CD.
Labeled leukocyte scintigraphy can help in the locali-
zation of abscesses when the other methods have been
inconclusive.
3.4. Upper GI lesionsECCO–ESGAR statement 3F
Contrast studies or cross sectional imaging can be
used to detect upper GI strictures [EL 4].
The prevalence of CD involving the upper gastrointestinal
(GI) tract is low compared with ileal and colonic
disease. Approximately 10%–15% of patients have associ-
ated upper GI lesions.135 Esophageal CD has been shown
to affect the distal third of the esophagus alone in 80%,
the middle and lower third in 15%, and the entire
esophagus in 5%.
Data on imaging in esophageal CD is sparse and sizeable
series are lacking, with essentially absent data for the
stomach. Cross sectional imaging may reveal ulcers or
strictures in oesophageal CD but superficial lesions are
difficult to detect, underscoring the importance of endos-
copy in the diagnosis of oesophageal CD. Endoscopy with
tissue biopsy is useful to exclude other common esophageal
disorders. The most commonly described findings on endos-
copy include aphthous ulcers, superficial erosions, and late
stage development of stricture and cobblestoning of the
mucosa.136
One study discussed inflammatory conditions of the
esophagus137 where diagnosis was made with endoscopy,
barium studies, CT scan and a biopsy. Recently, the presence
of an esophagobronchial fistula formation in a patient with CD
was described in a case report.138 The authors indicated
barium swallow as the initial test of choice to identify
esophagobronchial fistulae.
3.5. Global bowel damage
New tools, such as the Lémann score, have been proposed
and are in the process of validation. This score measures
damage resulting from inflammatory, stenosing or pene-
trating lesions, as well as that resulting from permanent
loss of intestine after surgery4 The score would allow
measuring the cumulative bowel damage at a specific time
in a patient's history, measuring the progression of bowel
damage over time in cohorts of patients and in clinical
trials. It would facilitate identification of patients with CDat high (or low) risk of rapid damage progression, and compare
the effects of treatment strategies on the progression of
bowel damage.
3.6. Monitoring therapeutic responsesECCO–ESGAR statement 3G
Cross sectional imaging, in particular MRI, can
be used for monitoring therapeutic response.
However, there is a delayed timeline as
compared to clinical or endoscopic changes
[EL 3].
Mucosal healing has been associated with sustained
clinical remission, and reduced rates of hospitalization and
surgery. CD is a transmural process, so full-thickness small
bowel healing or remodeling could be important end points.
However, only few studies have explored how radiologic
parameters of active inflammation change over time during
medical therapy.
3.6.1. Ultrasonography
A prospective study was carried out on 15 patients with CD,
using small intestine contrast ultrasound (SICUS) to assess
changes caused by anti-inflammatory treatment and its
relationship with the clinical and biological response.139 The
parameters were measured before and after 6-month
anti-inflammatory treatment. In 13 patients the slope of the
enhancement curve and the area under the enhancement
curve were significantly lower after anti-inflammatory
treatment (P b 0.05) with a significant correlation with
the Crohn's disease activity index (CDAI) score (=0.85,
P b 0.05). However, changes in US findings were not
compared with another objective measure of lesion severity,
namely endoscopy.
Another prospective study was carried out on 24
consecutive patients with CD, using US to assess changes
induced by anti-TNF therapy and its relationship with the
clinical and biological response.140 The parameters were
measured one week prior to the induction treatment and
two weeks after. The anti-TNF therapy caused a significant
reduction in the thickness of the bowel wall (P = 0.005) and
Doppler flow (P = 0.02), leading to the disappearance of US
changes in 50% of the patients. However, sonographic
normality was only achieved in five out of 17 (29%) patients
with a clinical and biological response, and could not
differentiate between those with and without clinical and
biological response (P = 0.27). This study also lacked an
established gold standard for assessment of mucosal
healing. Although the overall data seems promising, US is
not ready to be used in clinical practice for assessment of
therapeutic responses.
3.6.2. Computed tomography
A recent retrospective study of 63 patients with CD who
underwent CT before and at variable time lengths after
initiation of infliximab showed that resolution of lesions
can be centripetal (from the ends inward) and that up to
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normalization of what was abnormal small bowel.141 Poor
to fair correlation was found between CT features of
response and improved clinical symptoms (kappa 0.26),
improved endoscopic appearance (kappa 0.07), and
reduction of CRP (kappa 0.30). When comparing re-
sponders (complete and partial) with nonresponders,
only the presence of “comb sign” on the index CT was
predictive of radiologic response (P = 0.024).
3.6.3. Magnetic resonance imaging
Various studies have shown responsiveness of MRI lesions or
indexes to therapeutic interventions. A study in 18 patients
prospectively assessed the effect of 6 month adalimumab
treatment with moderate-severe stricturing ileal CD.142
Before and 6 months after the beginning of adalimumab
treatment, patients underwent ileocolonoscopy and MRE.
MRE activity index was of 7.11 ± 1.18 and 5.1 ± 2.22,
respectively. Improvement in inflammatory parameters
was observed both in relation to the MRE activity index
(P = 0.003) and the SES-CD score (P = 0.0005), compared
with 6 months before. Authors conclude that MRE activity
index could be helpful for assessment of healing of
inflammatory lesions.
3.6.4. Positron emission tomography
CD strictures usually represent a continuum of active inflam-
mation, muscular hypertrophy, and fibrosis: all are present, in
varying degrees, in any particular stricture.109 Most strictures
(defined as luminal narrowing with prestenotic dilation) will
have some imaging findings of inflammation, but these imaging
findings do not correlate with reversibility of the stricture.
Combined PET–CT enterography may overcome this weakness
because poor uptake of the PET tracer FDG may predict failure
of medical therapy.143 Although a study of inflammatory and
fibrotic strictures demonstrated a range of FDG uptake,
patients with predominant fibrosis had lower FDG uptake.1444. Colon and rectum, CD and UC excluding cancer
Most studies employing US, MRI and/or CT for assessment of IBD
activity included CD patients with small bowel rather than
colonic disease. Moreover, not all studies describe disease
location, activity and severity. Different designs, samples
(often small) and technical aspects confound observed differ-
ences between techniques. In the present section, only studies
comparing imaging findings to a reliable reference standard
(endoscopy and/or surgery) in patients with both suspected and
established IBD are considered.4.1. Diagnosis of colonic inflammationECCO–ESGAR statement 4A
MRI, CT and US imaging are an adjunct to
endoscopy for diagnosis of colonic IBD. MRI and
CT have higher sensitivity for examining locations
difficult to access by US [EL 2].ECCO–ESGAR statement 4B
The performance of imaging depends on the type
of colitis and severity [EL 1].
Transabdominal US and MRI have a high accuracy
for assessing the activity and severity of Crohn' s
colitis [EL:1b, RG:A]; the performance in UC is
less clear and the role of CT for distinguishing
quiescent from active colonic IBD is currently not
defined.
White blood cell scintigraphy can detect colon
inflammation and can be used as an additional
technique [EL 2].
The accuracy of cross-sectional imaging techniques for
the assessment of disease activity and severity is high, and
sufficient to guide clinical decisions in the majority of
clinical circumstances. Direct and indirect comparisons of
the relative accuracy of US, CT and MRI for diagnosis of
disease activity and severity both in UC and in CD show that
the techniques provide similar sensitivities and specificities
overall. 47,146-156 However, accuracy of each technique may
vary depending on the location of the colonic segments
being analyzed.152-155
4.1.1. Ultrasonography
The role of US to assess activity has been most extensively
investigated for small bowel CD. When considering colonic CD,
US is most accurate in the sigmoid/descending colon, followed
by the caecum/ascending, and transverse colon, while
accuracy for rectal disease is poor.151,158
A systematic review of 6 studies investigating US for
assessment of ileo-colonic CD found sensitivities ranging
from 63% to 100% and specificities from 77% to 100%.106 A
study using a heterogeneous case mix (48 CD, 23 UC, 3
unclassified colitis, 44 controls),156 reported high sensitivity,
specificity and accuracy for high resolution sonography when
assessing CD activity (per-patient basis: 94%, 67% and 93%;
per-segment basis: 80%, 67% and 80%, respectively). It has
been suggested that contrast-enhanced Doppler USmay assess
CD inflammatory activity within colonic strictures impassable
by endoscopy.159–161 A comparable accuracy was shown by
CEUS and Doppler US, although correlation with CDAI was
strongest for CEUS than for US.8 Several studies found
significant correlations in CD severity between US (using wall
thickness) and colonoscopy,8,9,116,132,153,162-165 barium con-
trast132,169 CT/MRI, surgery or histology.8,151
Some studies reported good correlations between various
clinical and endoscopic activity indices and severity of
colonic lesions as assessed by hydrocolonic sonography,68
but these findings have not always been reproduced; other
studies found weak or no correlation between CD severity as
assessed by US and several clinical and hematochemical
parameters of inflammation.116,132,145,151,153,155,164
Because UC involves the mucosa continuously from the
rectum, colonoscopy with biopsy is the reference standard
for assessment of disease extent, activity, and severity.
Nevertheless, in experienced hands, US is an alternative,
particularly in patients not requiring biopsy and/or with
severe comorbidities. In 4 studies assessing the diagnostic
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100% and specificities from 82% to 90%.166 Current evidence
indicates that in UC diagnostic accuracy of US is also related
to disease site, as sensitivity is high for sigmoid/descending
colonic disease (reaching 97%),151 but low for rectal
disease.167 The utility of US for assessing activity has been
assessed in a study including 38 IBD patients (12 UC) and 6
controls,155 the mean colonic wall thickness was 3.2 mm in
both CD and UC, being higher in moderately (n = 46;
P b 0.001) or severely inflamed bowel (n = 20; P b 0.001)
compared to normal segments (n = 58). However, these
studies frequently depend on specifically experienced
sonographers and may not be generalizable.
4.1.2. Computed tomography
The diagnostic utility of CT in CD colitis was investigated in 3
studies including 85 patients.119,168,169 Sensitivity and
specificity for activity ranged from 60% to 90% and from
90% to 100%, respectively. Lowest sensitivity was achieved
when luminal contrast was omitted.119 One study compared
CT-colonography and high-resolution video-endoscopy168;
the colonic wall thickness on CT correlated with the presence
of ulceration (r = 0.69, P b 0.01), active CD (r = 0.81, P =
0.001), pseudopolyps (r = 0.72, P = 0.01) and fistulae (r = 0.77,
P = 0.002) at endoscopy. Increased vascularity correlated with
mucosal inflammation (r = 0.72, P b 0.01) while no correlation
was found between CDAI and any CT finding.168 A role for CT
colonography (virtual colonoscopy) has been proposed to
assess postoperative recurrence, although the observed false
negative rate supports continued use of colonoscopy,170 unless
strictures are impassable.
Few studies have investigated CT to assess UC, finding an
overall sensitivity of 74% when using CT enterography to
detect colonic inflammation.171,172 Although preliminary stud-
ies in small samples173,174 report good correlation between
disease extent by colonoscopy and PET/CT (κ 55%; P = 0.02),
further studies are needed. A study of CT in 21 patients,168
found loss of haustration, a rigid bowel wall, and bowel
thickness were moderately correlated with UC severity
(r = 0.612). Overall, the limited available data using CT or
CT colonography in UC does not demonstrate adequate
diagnostic performance175,176 and colonoscopy remains the
reference standard. Indications for CT are currently
restricted to patients with impassable stenoses or severe
comorbidities where colonoscopy is contraindicated.176
4.1.3. Magnetic resonance imaging
MRI may provide useful information in colonic CD, including
wall thickening, presence of ulcers, depth of mural
penetration, edema, loss of haustration, polyps, and
extraluminal findings/complications, although mild dis-
ease may not be detected.150 13 studies investi-
gated colitis activity using an appropriate reference
standard.133,146,148–150,152,154,157,169,177–181 Per-patient
analysis133,152,157,178–180 found high sensitivity and specificity,
ranging from 78% to 100% and from 46% to 100%, respectively.
On a per-segment analysis,146,148–150,154,166,169,177,181 sensitiv-
ity and specificity ranged from 55 to 87% and from 84% to 98%
respectively.166 The sensitivity and specificity of MRI were
investigated in 8 studies using colonoscopy as reference
standard.146,148–150,166,179–181 Overall, good correlation was
found between endoscopic severity and MRI findings, which washigher with luminal distension.148,166,181 Significant correlation
was observed between MRI and endoscopic activity indices in 5/
6 studies (ranging from r = 0.34 to r = 0.85).148,149,153,179–181 In
3 of these, an MRI activity index significantly correlated with
the endoscopic activity index, including both qualitative148 and
quantitative indices.149,150 In 4 studies describing a segmental
analysis,148–150,179 768 segments were analyzed, of which 230
were active (29%). High correlation between endoscopic
activity and MRI (P b 0.001) was reported.148,149,179 All studies
found no or very weak correlation between MRI findings and
both clinical and endoscopic indices of inflammation or
alterations in biomarkers.117,131,133,150,153,177,179,180 However,
a total MRI score (MR-score-T) did correlate with both a
simplified endoscopic activity score (r = 0.539, P b 0.001)
and with the CDAI (r = 0.367; P b 0.004).148 Overall, MRI
may be useful to assess CD colitis after incomplete
colonoscopy, in patients not requiring biopsy, or those
with severe co-morbidities, and where extraluminal compli-
cations are suspected.117,131,133,146,148–150,177–181
Findings of initial studies suggesting that MRI may be
valuable for assessment of UC,182,183 were later substan-
tiated in larger studies.184–188 Indeed, various studies
reported higher sensitivity for MRI in UC (58.8%–68%) than
CD (31.6%–40%).146,189 In a larger study,148 the accuracy of
diffusion-weighted (DWI) MRI for colitis was also greater in
UC (n = 35) than CD (n = 61) (P b 0.003). A segmental MRI
score (MR-score-S) N 1 had a sensitivity and specificity of
89% and 86% when compared with endoscopic assessment
of inflammation (AUC 0.920, P b 0.0001). For CD, a
MR-score-S N 2 detected inflammation with a sensitivity and
specificity of 58% and 84% (AUC = 0.779, P b 0.0001). MRI
performs better in moderate-to-severe UC190 than in mild
disease.
4.1.4. Other techniques
Scintigraphy with radiolabeled leucocytes is a valid option to
cross-sectional imaging to demonstrate disease activity in
CD. A normal scan makes very unlikely the presence of active
disease with high accuracy.51,56,191
4.2. Diagnosis of colonic complications
4.2.1. Penetrating complicationsECCO–ESGAR statement 4C
US, CT, and MRI are useful for detection of
penetrating complications of the colon, although
accuracy of these techniques for this type of
lesions is less well defined than for assessment of
colonic inflammatory changes [EL 2].
This section is devoted to complications mostly related
to colonic CD, including fistula, abscesses and stenosis.
Only studies reporting results for colonic lesions and with
an adequate reference standard (i.e. endoscopy and/or
surgery) are considered.
Three studies investigating US for diagnosis of fistulizing
complications75,132,192 found sensitivities ranging from 71%
to 87%, with specificities ranging from 90% to 100%. Only one
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adequate reference standard, finding sensitivity and speci-
ficity of 68% and 91% respectively.75 The diagnostic utility of
MRI for intraabdominal colonic fistulas was determined in
three studies,131–133 reporting sensitivities between 71% and
100%, and specificities from 92% to 100%. In the only study
reporting results separately for colonic and small bowel
segments, similar sensitivity, specificity and overall accura-
cy were found for all segments.131
Various studies have compared the performance of
different cross-sectional imaging modalities. The diagnos-
tic accuracy of CT and US for diagnosis of intra-abdominal
fistulas complicating CD was similar in a study using a
surgical reference standard: sensitivity and specificity
were 68% and 91% for CT compared with 87% and 91%
respectively for US.75 In another study using a combination
of endoscopy, barium studies, CT, and surgery as reference
standard, 17 cases with enteroenteric fistulas were
identified.132 US and MRI detected 14 (82%) and 12 (70%)
fistulas respectively. Specificity and accuracy were 100%
and 90% for US versus 92% and 80% for MRI.
The value of US for the detection of abscesses was
assessed in three studies using a surgical reference
standard,75,131,192 finding sensitivities ranging from 81% to
100%, with specificities of 92% to 94%. One study found that
intra-abdominal abscesses were correctly detected in 9/9
patients and excluded in 22/24 patients (sensitivity 100%,
specificity 92%).192 The higher accuracy reported in this
study may be due, at least partly, to patient selection by
excluding cases with lesions in anatomic areas that are
difficult to assess by US, in particular the stomach, the deep
pelvis, and the rectum.
The value of CT to detect intra-abdominal abscesses in
patients with CD colitis was investigated by two studies from
the same group75,162 showing sensitivities of 86 to 100% and
specificities of 95 to 100%. Two similar studies using
MRI131,179 found sensitivities of 75% and 86%, and specific-
ities of 91% and 93%.
A comparison of US and CT75 found that abscesses were
correctly detected in similar proportions (US 91%, CT 86%),
although overall accuracy was higher for CT (92%) than for
US (87%) because of US false-positives. Both methods missed
only deep abscesses: five by US in the entire series (three
interloop, one mesenteric, and one appendicular) and three
by CT (two interloop and one mesenteric). The combination
of CT and US did not significantly improve the diagnostic
accuracy overall.4.2.2. Detection of stenosisECCO–ESGAR statement 4D
Contrast enema or cross sectional imaging can
be used to diagnose and assess colonic strictures
and accuracy is improved with colonic distension
[EL 2].
Two studies found that US had high diagnostic accuracy for
detection of small bowel and colonic stenosis,192,193 with
sensitivities of 75% and 100%, and specificities of 93% and90%. In the single study reporting small bowel and colonic
findings separately, US sensitivity was not significantly
affected by the site of stenosis.193
None of the four studies investigating the utility of CT for
assessment of stenosis, and using an appropriate reference
standard, provided data regarding colonic steno-
ses.73,111,120,152 Based on the high accuracy of CT for
detecting small bowel stenosis (sensitivity 85% to 93%,
specificity 100%) it is plausible that CT may be useful for
similar colonic lesions.
Four studies investigated the utility of MRI for the
detection of colonic stenosis in CD,131,133,179,194 with sensitiv-
ities ranging from 75% to 100%, and specificities from 91% to
100%.
At the time of writing, there is no direct comparison of
cross sectional imaging techniques for diagnosis of colonic
strictures.
4.2.3. Limitations of selected studies
Studies using a surgical reference standard will have a
spectrum bias towards more severe intestinal complications in
CD, and likely overestimate diagnostic sensitivity, due to the
presence of more severe lesions, and diagnostic specificity due
to a higher prevalence of lesions in the operated population.
Comparisons of diagnostic accuracy are also limited by
different diagnostic thresholds and criteria across studies;
standard definitions for individual complications from a
radiologic perspective for each of the available techniques
are elusive. Such definitions would facilitate comparisons
across studies and overall conclusions. Some recent progress
has been made in this regard for US and CT; standard
definitions are currently being developed for MRI.
4.3. Value for therapeutic monitoringECCO–ESGAR statement 4E
MRI is accurate for therapeutic monitoring in
colonic Crohn's disease [EL 2]; the accuracy of
other modalities is not well defined.
Mucosal healing has emerged as an important treatment goal
for patients with inflammatory bowel disease. Various studies
have assessed the value of cross sectional imaging techniques
for therapeutic monitoring in CD, using US,108,167,195 and CT,196
although the terminal ileum was also assessed in these
studies, and results are not reported separately for colonic
disease.
The utility of US for assessing activity and drug response
has been compared with colonoscopy,108,167,195 with high
concordance (weighted κ between 0.76 and 0.90). US may
also provide prognostic information; moderate/severe US
scores at 3 months were associated with increased endo-
scopic activity at 15 months (OR 5.2; 95% CI 1.6–17.6 and OR
9.1; 95% CI 2.5–33.5, respectively).167
The value of CT was assessed in a retrospective North
American study including 63 patients with CD receiving
infliximab.196 Of 105 lesions, 21 (20%) were colonic. Poor to
fair correlation was found between CTE features of response
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endoscopic appearance (kappa 0.07), and reduction of CRP
(kappa 0.30). When comparing responders (complete and
partial) with nonresponders, only the presence of “comb
sign” on the index CTE was predictive of radiologic response
(P = 0.024).196 Preliminary results of ongoing studies show
that MRI has a high accuracy for monitoring therapeutic
responses using endoscopy as a reference standard, in terms
of responsiveness and reliability.5. Perineum including anus, genital tract
5.1. Assessment of perianal diseaseECCO–ESGAR statement 5A
MRI is the most accurate diagnostic imaging test
for perianal CD with accuracy surpassing exami-
nation under anesthesia, and is recommended
during the initial diagnosis unless there is a need
for immediate drainage of sepsis [EL 1].
Endosonography (with or without hydrogen per-
oxide) is superior to clinical examination and is an
alternative to MRI [EL 2].
The diagnosis and classification of perianal disease are often
reached using a combination of both clinical and imaging
findings. Examination under anesthesia (EUA) in the hands of
an experienced surgeon has been considered the gold standard
in the assessment of perianal CD as it provides opportunity for
both full staging and treatment such as drainage of sepsis and
placement of non-cutting setons.197 Many comparative studies
have been performed evaluating US and MRI in the diagnosis of
perianal CD fistulae,198–209 pouchitis and urogenital compli-
cations. Both US (with and without hydrogen peroxide) and
MRI are able to identify and classify fistulous tracts with good
accuracy. The diagnostic accuracy of MRI ranges from 80 to
100% in most reported studies. The diagnostic accuracy of
endoanal US (EUS) is variable and in general ranges from 50 to
100%. In general endoanal probes are utilized, although
studies using alternative approaches such as transperineal
have reported high sensitivity.210
Schwartz et al.,46 in a prospective blinded study comparing
EUA, MRI and EUS demonstrated a diagnostic accuracy of 91%,
87% and 91% respectively with 100% accuracy when any 2 of
the tests were combined. A larger prospective clinical trial
comparing preoperative digital rectal examination, US and
body-coil MRI showed MRI to be superior to US for abscess
detection, which in turn was superior to clinical examination
(85%, 75% and 33% sensitivity respectively). Good data exists
demonstrating that MRI may correctly change surgical man-
agement in patients with perianal CD.198,211 Given its non-
invasive nature, MRI should precede simple diagnostic EUA
unless there is a need for immediate drainage of sepsis.
Although endoscopic US has been found to have high diagnostic
accuracy,46 its use may be limited by luminal stenoses and
transvaginal and transperineal US techniques may be more
useful in this instance.212The perianal disease activity index (PDAI)214 is a clinical
scoring system which has been used and validated in clinical
studies both at diagnosis and to measure treatment response.
CDAI measures intestinal and extraintestinal manifestations of
CD and as such is not accurate in assessment of perianal
disease specifically.215 The fistula drainage assessment has
been used in several clinical trials of medical therapy,216–219
but is very much investigator dependent and has not been
validated in large studies. A single retrospective study has
evaluated the PDAI scoring system, where high scores
predicted short term surgical outcome, but this has not since
been validated.220 MRI classifications of fistula severity have
been proposed such as the system published by Van Assche et
al.,221 but have limited use so far outside formal clinical trials.
There is no single widely accepted and validated severity
clinical scoring system for perianal fistula in CD. Both the
PDAI and fistula drainage assessment may be used to
measure fistula activity in clinical trials.
ECCO–ESGAR statement 5B
Undetected or untreated fistulae extensions and
abscesses are the major cause of treatment
failure. Imaging, particularly using MRI, is highly
accurate in detecting such complications and for
treatment planning [EL 1].
Full and accurate staging of perianal fistulae complicating
CD is essential for therapeutic planning and ultimately
achieving optimal clinical outcomes. Data suggest that the
finding of rectal inflammation and or stenosis has prognostic
implications and is relevant in determining the treatment
approach. Rectal inflammation often indicates the presence
of complex fistulae and associated complications such as
abscesses.2 Often endoscopic examination of the rectum and
colon is needed to determine the presence of macroscopic
inflammation and/or anal stenosis and is useful for planning
treatment of perianal CD.
Undiagnosed extensions and abscesses are the major
cause of recurrent disease after attempted surgical
cure.199 Furthermore, full knowledge of the presence of
these complicating abscesses and extensions is required
before appropriate deployment of medical therapy, partic-
ularly with anti-TNF.222
Good evidence is available to inform use of investigations for
staging and detection of complications prior to therapy. Notably
two prospective and blinded studies have evaluated the effect
of preoperative MRI on clinical outcome after surgical treat-
ment for perianal fistula disease.198,199 Both studies showed
that MRI revealed additional and clinically relevant informa-
tion to the surgeon performing EUA. Recurrence rates after
fistula surgery are improved if the findings of preoperative MRI
are used to inform the surgical approach. US also has high
reported accuracy for detecting complications of perianal
CD46,223–225 and may also be useful in treatment planning,
particularly in non-recurrent disease. Use of US may be
restricted due to patient discomfort, and the field of view
is less than external coil MRI. Comparative prospective
data using a robust outcome based reference standard
suggests that MRI is superior to US for detecting complicating
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recurrent or suspected complex disease.
5.2. Assessment of therapeutic responses in perianal
diseaseECCO–ESGAR statement 5C
MRI and endosonography are both superior to
simple clinical evaluation at assessing treatment
response, particularly for detecting residual ab-
scesses, and either should be considered prior to
significant changes in, or cessation of, surgical or
medical therapy [EL 2].
The definition for fistula healing in the literature is varied, and
there is no consensus onwhen a first or definitive evaluation of
fistula healing should be performed.215 The PDAI214 has been
validated in patients undergoing treatment with antibiotics
and azathioprine and has been used as a secondary end point
for infliximab trial for the closure of perianal fistulae.214
Subsequent trials on biologics and immunomodulators have
used physical examination using gentle finger compression
to assess whether drainage occurred to define a primary
end point of N50% reduction in the number of draining
fistulae on two or more consecutive study visits.218,222,227
There are no studies to compare the reproducibility of this
method to that of the PDAI.
MRI is increasingly used to assess fistula healing, particularly
during medical therapies.221,228,229 Various MRI classifications
have been proposed, including the Van Assche score221 which
considers the number of fistulae, localization, extensions, T2
hyperintensity, abscesses and rectal involvement. Changes in
contrast enhancement have also been proposed as a means to
monitor fistula activity.208
There is no consensus on when the first or definitive
evaluation of fistula healing should be performed. It has been
shown that fistulae may reopen after cessation of therapy and
studies using MRI findings as a more stringent endpoint of deep
fistula healing suggest that MRI221,222,229 and endoanal US224,230
may be useful for identification of fistulae that show external
closure but retain an internal fistula tract. This suggests that
imaging assessment of deep healing is superior to simple clinical
evaluation, although long-term comparative studies are
lacking. Direct comparisons between MRI and endoanal
ultrasound are also lacking although use of MRI is more
clinically widespread.
5.3. Urogenital complicationsECCO–ESGAR statement 5D
In urogenital CD, clinical examination, EUA, MRI,
CT and ultrasound may all be used. Contrast
studies have a diminishing role [EL 4].
Many imaging modalities including MRI, fluoroscopy, CT and US
may be employed for diagnosis of urogenital complicationssuch as entero-vaginal and entero-vesical fistulae. There
remains a lack of controlled data in this field with little
evidence to recommend one technique over another. Small
series report successful use of MRI in detecting pouch related
complications such as fistula and leaks.213
US and MRI are superior to clinical examination in classifying
fistulae and their findings should inform final classification.
Clinical examination should be supplemented with imaging
and/or EUA for full and accurate fistula classification.5.4. Anorectal diseaseECCO–ESGAR statement 5E
The role of imaging in anorectal stricturing or
carcinomatous transformation is limited to staging
of confirmed disease and assessing the severity of
known stricture [EL 4].
Confirmation of CD related anorectal malignancy
should be made using established clinical, endo-
scopic and histopathological criteria [EL 4].
Long term complications of perianal CD include the
development of luminal stenosis and anal carcinoma. The
limited available evidence suggests that imaging is insensitive
for diagnosis of carcinoma,231–233 and use is limited to staging
of confirmed disease. Confirmation of carcinomatous trans-
formation in the context of chronic CD related fistulation
should be made using established clinical and histopatholog-
ical criteria. Both MRI and US have been used in the context of
staging anal cancer although the larger anatomical coverage
afforded by MRI suggests that it should be used as first line.234
Clinical evaluation and conventional endoscopic techniques
remain first line for detection luminal stenosis.6. Liver and biliary tract
6.1. Non-invasive radiological techniquesECCO–ESGAR statement 6A
Ultrasound is the first-line non-invasive imaging
procedure in the work up of elevated liver enzymes
and to differentiate intra- from extra-hepatic
cholestasis [EL 1].
Magnetic resonance cholangiopancreatography
(MRCP) should be considered in patients with
unexplained cholestasis if ultrasound and labo-
ratory results are non-diagnostic [EL 1].
Endoscopic ultrasound (EUS) is an alternative to
MRCP for evaluation of distal biliary tract ob-
struction [EL 2].
Elevated liver or cholestatic enzymes in IBD should be further
investigated.235 If drug induced liver toxicity is unlikely,
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Other hepatobiliary diseases more frequently observed in
IBD than in normal controls including non-alcoholic fatty liver,
non-alcoholic steatohepatitis, gallstone disease, reactivation
of hepatitis B, primary biliary cirrhosis and liver cirrhosis
should also be considered.
US is usually the initial diagnostic step to exclude intra-
and extrahepatic cholestasis or lesions within the liver as
US is sensitive and specific, relatively inexpensive and
non-invasive.236–238 CT is associated with radiation expo-
sure, is highly specific and has moderate sensitivity for the
detection of bile duct narrowing and choledocholithiasis.239
ERCP has been considered to be the gold standard for imaging
of the biliary tract. However, because of potential complica-
tions it should be restricted to selected cases. MRCP has
been shown to be a safe alternative to ERCP in many cases and
has similar sensitivity and specificity in detecting bile duct
abnormalities.240,241
EUS is equivalent to MRCP in detecting common bile
duct abnormalities.242–244 In endoscopic units with good
experience with this method, EUS may therefore be used
instead of MRCP for detection of bile duct stones and
other lesions that cause extrahepatic obstruction. There-
fore, when the requirement of intervention is unclear,
MRCP or EUS should be performed first, in order to avoid
ERCP.245,246
6.2. Endoscopic retrograde cholangiopancreatographyECCO–ESGAR statement 6B
Diagnostic endoscopic retrograde cholangiopancre-
atography (ERCP) should be reserved for highly
selected cases in patients with normal high quality
MRCP, but high suspicion for PSC, when cytology is
required or in patients with contraindications for
MRI due to high complication rate [EL 2].
ERCP should also be reserved for patients where a
therapeutic procedure is anticipated such as
stenting or balloon dilatation [EL 2].
For many years ERCP has been considered to be the gold
standard to detect PSC. In recent years many studies have
confirmed that MRCP has similar diagnostic value as ERCP
in detecting PSC.241,247–249 Sensitivity for detection of
small duct PSC may be slightly higher in ERCP even though
MRCP is almost as accurate as ERCP.241,248 Recent
meta-analysis shows that MRCP has excellent accuracy
(area under the curve of 0.91) in the diagnosis of PSC
which supports that initial MRCP with negative results
followed by ERCP would be a cost-effective approach to
diagnosing PSC.241 MRCP should therefore be first line
procedure and ERCP should be restricted for highly selected
cases. Differentiating benign strictures in PSC from
cholangiocarcinoma is still a diagnostic challenge.246 In a
prospective study for evaluation of bile duct strictures
comparing ERCP, MRCP, CT and EUS, sensitivity and specificity
relating to bile duct strictures for diagnosis of malignancies are
85%/75% for ERCP, 85%/71% for MRCP, 77%/63% for CT and79%/62% for EUS.250 However, ERCP may be associated
with significant complications such as bleeding after
sphincterotomy in 2%, pancreatitis in 3–5%, cholangitis in 1%
and procedure related mortality in about 0.4%.251–253 ERCP
should therefore be restricted to cases with extrahepatic
obstruction with need for endoscopic intervention, when
intraductal ultrasound, histology or cytology is required.254–259
Other reasons to perform ERCP may be contraindications for
MRI. Patients with established PSC should undergo regular
screening in order to detect abnormalities of the biliary
tract suspicious for hepatobiliary malignancies in particular
cholangiocarcinoma. First line diagnostic procedures to follow
up patients with PSC are ultrasound and MRCP.260 Bile duct
strictures and progressive marked dilatations in patients
with PSC are suspicious for cholangiocarcinoma and should
be further investigated with ERCP for cytology, histology and
eventually intraductal US.257,2586.3. Ultrasound-guided liver biopsyECCO–ESGAR statement 6C
Ultrasound guided liver biopsy should be consid-
ered for diagnosis of small duct PSC and other liver
diseases in patients with otherwise unexplained
intrahepatic cholestasis, normal high quality MRCP
or ERCP and inconclusive laboratory work up [EL 3].
In patients with otherwise unexplained intrahepatic
cholestasis, normal high quality MRCP or ERCP and a
negative AMA test a liver biopsy should be considered for
diagnosis of small duct PSC and other liver diseases. Patients
with small duct PSC have biochemical and histological
features compatible with PSC while having a normal
cholangiogram.260,261 In a large multicenter trial small
duct PSC was associated with IBD in about 80%.262 78% of
these patients had UC, 21% had CD. Small duct PSC appears
to be a distinct form of hepatobiliary disorders in IBD
patients which can only by diagnosed by histopathological
features and with better prognosis than PSC.263–2657. Emergency situations
7.1. Gastrointestinal bleedingECCO–ESGAR statement 7A
Diagnosis and management of gastrointestinal
hemorrhage remain a domain of endoscopy. If the
bleeding cannot be located by endoscopy CT or
catheter angiography should be performed, unless
the patient requires immediate surgery [EL 1].
Gastrointestinal bleeding is a common cause for hospital
admission that results in significant morbidity for patients
affected by IBD. Identifying the source of bleeding
573Imaging techniques for assessment of inflammatory bowel diseasecan be difficult since many patients bleed intermit-
tently or stop bleeding spontaneously. With the con-
tinued advances in endoscopic technology, colonoscopy
and gastroduodenoscopy have become not only diag-
nostic but also a useful therapeutic tools in the manage-
ment of acute gastrointestinal bleeding (GIB) in stable
patients. Despite the lack of IBD specific studies,
colonoscopy performed within the first 24 h of admis-
sion may result in a definitive diagnosis in up to 96% of
patients.266,267
After standard endoscopy, in the setting of obscure
gastrointestinal bleeding double balloon enteroscopy (DBE)
might be the initial test to perform.268 According to a recent
metanalysis DBE seems to have similar diagnostic perfor-
mances as capsule endoscopy (CE), with the main advantage
to be also an interventional procedure.269
CE is superior to push enteroscopy for diagnosing
clinically significant small bowel pathology in patients with
occult gastrointestinal bleeding; a recent metaanalysis
reported the yield for CE and push enteroscopy of 63% and
28% respectively.270
Diagnosis and management of acute gastrointestinal hem-
orrhage in IBD patients have been mainly investigated in
retrospective studies and case series.
The most recent study included 123 patients with
gastrointestinal hemorrhage of obscure origin that was
investigated with capsule endoscopy (CE) in combination with
multidetector CT. The study showed integrating the pro-
cedures improved the diagnosis, but that for CD lesions, CE
was superior to CT in diagnostic value.271
Despite the lack of IBD specific studies on the value of
CT in acute gastrointestinal bleeding, a recent prospective
study evaluated the accuracy of this technique for detec-
tion and localization of acute massive gastrointestinal
bleeding, using angiography as reference standard, showing
that overall patient-based accuracy for detection of acute
GI bleeding was 88.5%.2727.2. Toxic megacolonECCO–ESGAR statement 7B
In acute, severe colitis a plain abdominal radio-
graph is an acceptable first study to detect toxic
megacolon defined by a mid transverse colonic
dilation N5.5 cm. In equivocal or selected cases CT
could be used as the primary imaging modality to
screen for complications (e.g. perforation, ab-
scess, thrombosis, ischemia) that require emer-
gency surgery. Toxic megacolon is also predicted
by the extent of small bowel and gastric distension
in most patients with severe colitis [EL 3].
Toxic megacolon represents a serious complication of
mainly inflammatory or infectious conditions of the colon,
commonly associated with IBD, i.e., UC or ileocolonic
CD.273Diagnosis is made by clinical evaluation for systemic
toxicity and imaging studies. Detection of colonic
dilatation greater than 5.5 cm by means of plain abdom-
inal X-ray is still the most established radiological
criterion of toxic megacolon. However, other radiolog-
ical signs, such as increased small bowel gas, persistent
small bowel distension and distension of the stomach,
mucosal islands, colonic dilatation and colonic deep
ulceration, may predict the failure of medical therapy
in patients with severe colitis, together with a higher
risk of developing toxic megacolon and the need for
colectomy.274–278
Small case series showed that in patients with toxic
megacolon, CT scan and transabdominal intestinal ultra-
sound may be promising alternatives providing additional
information.279,280 In particular, CT scan is potentially an
important tool in the diagnosis of abdominal complica-
tions including toxic megacolon, perforation or ascending
pylephlebitis. A study observed that among 18 patients
with toxic megacolon (4 with underlying UC) in 4 CT scan
found abdominal complications missed clinically and on
plain abdominal films.279 However, larger clinical studies
are warranted to assess the diagnostic benefit of radiolog-
ical studies in the assessment of toxic megacolon.7.3. Acute abdominal painECCO–ESGAR statement 7C
Abdominal ultrasound and plain X-ray should be
considered in all patients with acute abdominal
pain and established IBD. CT should be considered
in patients with suspected perforation and nega-
tive or inconclusive first line studies [EL 2].
Spontaneous free perforation is a rare but often serious
event in the clinical course of CD, and may be a result of
severe inflammatory lesions or a superimposed malignant
process, i.e., adenocarcinoma or lymphoma. It is estimated
that approximately 1–15% of patients with CD will present
with a free perforation initially or eventually in their disease
course.281,282
The early diagnosis of this condition is an important
determinant of survival. A study by Hattori et al. including
10 CD patients with free perforations showed that CT scan
was significantly more sensitive than plain radiography for
detecting free air in the abdomen at the time of
perforation.283 However, a retrospective review of CT
scans enrolling 76 patients with various diseases (including
5 CD patients) with proven alimentary tract perforation
showed that CT scan yielded 65 true-positive and 11
false-negative cases, including 1 CD patient with mesen-
teric phlegmon and obstruction and concluded that CT is a
valuable method for intestinal perforation but with a
sensitivity of 85.5%.284
It should be taken into account that frequently in
CD patients, intestinal perforation presents as a peri-
intestinal abscess that may be detected by cross
sectional imaging methods such as US, MRI or CT. A
574 J. Panes et al.recent systematic review showed that in this context the
three techniques have a high accuracy for identification
of fistulas, abscesses and stenosis (sensitivities and
specificities N 0.80), although US has false positive re-
sults for abscesses.367.4. Post-operative complicationsECCO–ESGAR statement 7D
Acute postoperative complications in IBD patients
(e.g. anastomotic leaks, abscesses, intestinal
intussusception, mesenteric vein thrombosis, ob-
struction) should be initially investigated by CT or
ultrasound followed by immediate CT if negative
or equivocal. Fluoroscopic studies are also effec-
tive for assessing anastomotic leaks, in particular
distal anastomotic leaks [EL 4].
Anastomotic leaks after intestinal surgery may be easily
diagnosed on clinical grounds due to their characteristic
presentation in the post operative period. However, some-
times this complication has no definitive signs and symp-
toms, and correct and prompt diagnosis by the radiologist is
necessary for successful management.
Although few studies have been designed to assess
the detection of these complications in CD patients,
most of the available data is derived from the surgical
literature.285
A prospective database of two colorectal surgeons carried
out over a 10-year period, showed that anastomotic leaks
are frequently diagnosed late in the postoperative period
and often after initial hospital discharge. In this study CT
scan was the preferred diagnostic modality when imaging is
required.286
On the other hand, other studies showed that most
postoperative CT features overlap between patients with
and without clinically important anastomotic leaks and
that CT studies performed on patients shortly after
abdominal surgery are not definitive. A negative CT study
does not rule out postoperative lower gastrointestinal
tract leak.287,288
Ileal-pouch-anal anastomosis (IPAA) surgery preserves
fecal continence for improved quality of life in patients
who require proctocolectomy for treatment of intractable
IBD. The main acute complication of IPAA includes anasto-
motic leak and abscesses. Leaks from the blind end of the
pouch and the pouch-anal anastomosis often result in pelvic
abscesses.
The detection of this complication is possible using
transrectal and transperineal US, although usually CT or
MRI scanning is required to delineate the full extent of the
complication and guide drainage.289,290 In this regard, pelvic
abscess associated with anastomotic leak in patients with
IPAA can be drained using either transanal or CT-guided
approach. Both are equally effective although there is a risk
of fistula induction at the drainage site after a CT-guided
drainage.2918. Special situations not emergencies:
postsurgery, cancer surveillance, ileoanal pouch
8.1. Post-surgical recurrenceECCO–ESGAR statement 8A
US, CT, MRI, SBFT and WBC scintigraphy detect
recurrence of CD after ileocolonic resection and
are complementary to endoscopy [EL 2].
US, CT, MRI, SBFT and WBC scintigraphy can be
useful as a follow-upmethod in patients after small
bowel surgery [EL 2].
Recurrence of CD after surgical intervention is a diagnosti-
cally and therapeutically challenging condition. Several
imaging modalities are available to reliably diagnose post
surgical recurrence including US, SICUS, SBFT, CT
enteroclysis or enterography including virtual colonoscopy,
MRI enteroclysis or MRI enterography, SBCE and WBC
scintigraphy.
Several authors had formerly emphasized the value of
abdominal US in the postoperative follow-up and confirmed
the observation of the bowel wall thickening as an indicator
for recurrence.292–295 SICUS has shown an excellent correla-
tion with the endoscopic Rutgeerts' score (P = 0.0001; r =
0.67) reaching 87.5% accuracy for detecting CD recur-
rence296 and is considered to be superior to standard
abdominal US in detecting postoperative CD recurrence
after ileocecal resection.297 Bowel wall thickening was
defined by thickness of more than 3.5 mm. SICUS prediction
of recurrence was found to be correct in 100% of cases and
confirmed by endoscopy297 These results were confirmed in
two additional studies298,299 who determined sensitivity,
specificity, positive and negative predictive values to be
61.5% (95% IC: 41 79%), 96% (95% IC: 78 100%), 94%, and 71%,
respectively.
SBFT should only be used if cross-sectional imaging
techniques are not available or very specific clinical questions
apply. SBFT or enteroclysis is able to visualize the presence,
extent and pattern of CD recurrence after ileo-colonic
resection, although providing a radiation exposure to the
patient.300
CT enterography or enteroclysis is an alternative to
endoscopy for assessing postoperative recurrence of CD
activity.301 Evidence for the value of CT enterography has
also been shown.302 CT colonography has been tested for
assessing the postoperative recurrence of CD with inconclusive
results due to false negative findings. It does however represent
an alternative to conventional colonoscopy in noncompliant
postsurgical patients with a rigid stenosis which does not allow
passage of the endoscope.170
MRI enteroclysis or enterography may be an alternative to
endoscopy as a diagnostic tool in post-surgical recurrence
evaluation in CD patients.142,303 Similar to the endoscopic
Rutgeerts' score for assessing post-surgical recurrence, one
study showed an objective evaluation using an MRI based
index of activity and severity for post-surgical recurrence.
This score achieved a high correlation with the endoscopic
575Imaging techniques for assessment of inflammatory bowel diseaseindex allowing differentiation between mild and severe
lesions304 and predicting the risk of clinical post-surgical
recurrence in CD patients.305
Although the Rutgeerts' score has been used to evaluate
the efficacy of several drugs, there is lack of information
whether mural healing changes seen by cross-sectional
imaging techniques are in parallel to the endoscopical
mucosal healing.
Scintigraphy with 99mTc-HMPAO or 111 In-oxide labeled
leucocytes (or white blood cells WBC scintigraphy) has been
reported as an alternative non-invasive technique for the
detection of recurrence of intestinal inflammation in CD
patients.306–309 It is able to provide information about the
localization, extent and severity of a disease recurrence.
Limitations of WBC scintigraphy are its relatively low specificity
due to the high frequency of false positive findings.300
Investigations on the usefulness of WBC scintigraphy in
assessing the early postoperative recurrence of CD are
sparse62,1408.2. Evaluation of the ileoanal pouchECCO–ESGAR statement 8B
Either Pelvic MRI or CT is recommended in
suspicion of ileoanal pouch septic complications
[EL3b; RG C] or CD of the pouch [EL 4].
Pouchography can assess functional disorders,
pouch strictures, afferent limb syndrome, pouch
fistulae and pouch leakage [EL 3].
Ileo-anal (IA) pouch is a well-established option for patients who
require surgery for UC. Despite excellent functional results the
short and long-term outcomes of IPAA are determined by the
occurrence of complications. These may be directly related to
the performed surgery or occur over the long-term. Immediate
postsurgical complications include leakage, abscess formation,
pelvic sepsis and fistula formation. More chronic disorders
following IPAA are pouchitis, cuffitis, irritable pouch syndrome,
pouch stricture, pouch sinus, afferent loop syndrome or small
bowel obstruction.310 Recurrence of CD may occur within the
pouch. Following surgery, up to 40% of patients have a single
episode of pouchitis311 within 12 months, a nonspecific
inflammatory condition at the ileal pouch reservoir, whereas
19% to 5% experience intermittent episodes and chronic
pouchitis.312–314 In addition to pouch endoscopy, diagnostic
imaging modalities are essential to help distinguish inflam-
matory from non-inflammatory conditions and to identify
extraluminal complications which require immediate
interventions.
Therefore, cross-sectional imaging modalities such as
CT- and MRE and MRI of the pelvis are key imaging modalities.
Functional assessment of mechanical disorders related to
the pouch such as pouch stricture, afferent loop syndrome
and obstruction can be successfully addressed with func-
tional radiographic techniques such as pouchography and
defecography. The choice of the most appropriate imaging
modality depends on the clinically suspected disorder, localexpertise and availability. Inflammatory and infectious
complications are best addressed with CT and MRI.315,316
Pelvic MRI can be used to assess recurrence of CD of
pouch. Pelvic CT and MRI showed high accuracy for detecting
IA inflammatory complications. Further larger series are
needed to confirm their utility and determine whether cross
sectional techniques may be helpful for differentiating
pouchitis from CD recurrence.
Barium-enhanced radiography (pouchography) is accept-
ed for diagnosis of inflammatory complications of IA pouch
as well as for non-inflammatory conditions.
Despite a limited number of studies assessing the
postoperative outcome of IPAA with these techniques, both
CT and MRI are advocated to be useful in detecting mural
inflammatory changes. In one study315 mural and extramural
inflammatory lesions were found in 7 of 9 patients with
clinical suspicion of complicated ileoanal pouch confirmed
by histology. From these 7 patients, 2 had normal mucosa at
endoscopy. In another study a sensitivity of 78% and
specificity of 96% for detecting ileoanal pouch complications
(fistula, abscess or pouchitis) were observed; CT had a
higher sensitivity than pouchography for the detection of
inflammatory IPAA complications because extraluminal com-
plications cannot readily be assessed with pouchography.316 It
is important to emphasize that transmural inflammation of the
pouch detected on imaging is not necessarily due to CD, as it
can also be seen in chronic pouchitis. It has been suggested
that asymmetric pouchitis may indicate ischemia in contrast
to CD of the pouch or chronic pouchitis.317 Transmural disease
and wall thickening in the setting of IPAA are not pathogno-
monic of CD. Transmural inflammation shown by imaging or
histopathology can be seen in both CD and chronic
antibiotic-refractory pouchitis.318
A correlation of CT, MRI, pouch endoscopy and retrograde
pouchography findings with the clinical outcome found a
reasonable accuracy for diagnosis of strictures, fistulas,
sinuses and pouch leaks with all methods.213 CT had the
lowest accuracy for small bowel strictures (74%), and MRI for
pouch sinuses (68%). A combination of 2 imaging tests increased
the accuracy of diagnosis to 100%.
The afferent limb syndrome, defined as the obstruction of
afferent bowel loop at the junction of the pouch, can be
diagnosed by imaging techniques290; barium enema or CT
enterography can be used for the diagnosis of inflammatory or
fibrostenotic CD of the pouch. Finally, it is important to
emphasize that transabdominal ultrasonography is poor at
evaluating IA pouch complications due to their typically deep
location in the pelvis and inherent difficulty in visualization.8.3. Neoplastic lesionsECCO–ESGAR statement 8D
CT colonography or virtual colonoscopy is not an
alternative to colonoscopy in patients with proven
IBD for assessment of neoplastic lesions. Howev-
er, it is useful to detect cancer in clinical
situations where colonoscopy cannot be performed
(e.g. strictures) [EL 2].
576 J. Panes et al.There is no evidence that virtual colonoscopy by CT or MRI
may be of utility for surveillance of colorectal cancer in
patients with CD or UC. Considering the underlying inflam-
matory changes of the intestinal wall leading to permanent
abnormalities such as pseudopolyps, and the fact that a
significant portion of dysplastic lesions are flat at endoscopy, it
is conceivable that with current cross-sectional imaging
techniques both the number of false positive diagnosis and
the miss-rate for these lesions would be high. Therefore,
follow-up by periodical endoscopy including chromoendoscopy
is recommended for screening of dysplasia at least for
UC.319–321 There are no specific trials for CD but epidemiolog-
ical data suggest that patients with CD colitis have similar
incidences of colorectal cancer as of patients with UC.322,323
Therefore, in CD colitis a similar cancer surveillance algorithm
should be applied.
In patients with CD the risk for small bowel adenocarci-
noma is increased with a relative risk up to 159.324–326
Cumulative risks of 0.2% at 10 years and 2.2% at 25 years for
CD patients with small bowel disease at diagnosis have been
observed.147,3279. Implementation of recommendations
The statements and general recommendations of this
consensus are based on the highest level of evidence available,
but significant gaps remain in certain areas such as the
comparison of diagnostic accuracy between different tech-
niques, the value for therapeutic monitoring, and the prognos-
tic implications of particular findings.
Local expertise may have a significant influence on the
accuracy, and this is an additional factor to take into
consideration, although implementation of the techniques
that have shown the best diagnostic accuracy by properly
designed studies using reference standard (evidence levels 1
and 2), should be procured in every IBD reference center.
Finally, the costs incurred by different techniques have
not been considered for every patient situation. These costs
are highly variable between European countries, which
makes it difficult to factor this aspect into the recommen-
dations. Judicious considerations integrating the available
evidence, patient condition and costs are essential for the
best use of imaging techniques in IBD.Acknowledgments
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